These data confirm that the three surface proteins LYPD3, TACSTD2, and LY6D are reliable indicators of nuclear MRTF activity as well as prognostic markers of SMOi resistance in human BCC cells. This evidence concerns the gene LY6D and skin basal cell carcinoma.